in Re Caraco Pharmaceutical Laboratories Shareholder Litigation

CourtMichigan Court of Appeals
DecidedJune 13, 2017
Docket329933
StatusUnpublished

This text of in Re Caraco Pharmaceutical Laboratories Shareholder Litigation (in Re Caraco Pharmaceutical Laboratories Shareholder Litigation) is published on Counsel Stack Legal Research, covering Michigan Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
in Re Caraco Pharmaceutical Laboratories Shareholder Litigation, (Mich. Ct. App. 2017).

Opinion

STATE OF MICHIGAN

COURT OF APPEALS

In re CARACO PHARMACEUTICAL LABORATORIES SHAREHOLDER LITIGATION.

JOSEPH ALESSI, SANJEEV ARORA, MADHU UNPUBLISHED ARORA, and SARAH ARORA, June 13, 2017

Plaintiff-Appellants,

v No. 329933 Wayne Circuit Court CARACO PHARMACEUTICAL LC No. 10-014311-CB LABORATORIES, LTD., GURPARTAP SINGH SACHDEVA, FOLSOM F. BELL, TIMOTHY S. MANNEY, EDDIE MUNSON, SUN PHARMACEUTICAL LABORATORIES, LTD., and SUN PHARMA GLOBAL, INC.,

Defendants-Appellees. and

SUDHIR V. VALIA, SAILESH T. DESAI, JITENDRA N. DOSHI, and DILIP S. SHANGHVI,

Defendants

Before: M. J. KELLY, P.J., and BECKERING and SHAPIRO, JJ.

PER CURIAM.

In this shareholder derivative action, plaintiffs, former minority shareholders of Caraco Pharmaceutical Laboratories, Ltd. (Caraco), appeal as of right the trial court’s October 13, 2015 opinion and order granting summary disposition in favor of all defendants pursuant to MCR 2.116(C)(8) (failure to state a claim upon which relief can be granted). For the reasons stated below, we reverse the trial court’s ruling and remand the matter for further proceedings consistent with this opinion.

-1- I. PERTINENT FACTS AND PROCEDURAL HISTORY

Underlying facts1

During all times relevant to the instant appeal, Caraco was a Detroit-based manufacturer, marketer, and distributor of generic pharmaceuticals. Defendant-appellees Sun Pharmaceutical Laboratories, Ltd. (Sun Pharmaceutical), and Sun Pharma Global, Inc. (Sun Global), and defendant Dilip S. Shanghvi2 collectively owned approximately 75.8% of Caraco’s outstanding common stock. Sun Global, a trading and investment company, is a wholly owned subsidiary of Sun Pharmaceutical. Shanghvi is the controlling stockholder of Sun Pharmaceutical and Caraco’s Chairman of the Board since 1997, when Caraco and Sun Pharmaceutical entered into a stock purchase agreement that gave Sun Pharmaceutical substantial control over the day-to-day operations of Caraco. Since 1997, Caraco and Sun Pharmaceutical have entered into or renewed several purchase agreements that gave Caraco rights to manufacture certain generic pharmaceuticals and to market and distribute Sun Pharmaceutical’s products in the United States and its territories.

On December 3, 2010, Sun3 proposed to purchase the shares of Caraco that they did not already own at a price of $4.75 per share, and take Caraco private. Caraco’s Board of Directors authorized an Independent Committee, composed of defendants Folsom F. Bell, Timothy S. Manney, and Eddie Munson, to review the proposal and respond to the proposal’s terms, including the per share purchase price.4 Bell was the Independent Committee’s chair.

On December 27, 2010, Caraco announced that Sun Pharmaceutical would extend its existing distribution and marketing agreements with Caraco until January 28, 2012, but would terminate them thereafter. On January 3, 2011, Caraco announced that, contrary to its previous forecasts, it would not be able to restart production of various drugs by the end of fiscal year 20115. Upon the Independent Committee’s recommendation, Caraco entered into a definitive

1 The facts are derived from plaintiffs’ amended complaint. 2 Although a defendant in the action in the trial court, Shanghvi is not participating in this appeal. 3 “Sun” refers to Sun Pharmaceutical and Sun Global collectively. 4 During these events, Caraco’s board was comprised of Shanghvi, Sachdeva, the members of the Independent Committee, and defendants Sailesh T. Desai, and Sudhir V. Valia. Desai and Valia, like Shanghvi, are not participating in this appeal. Although the complaint lists Jitendra N. Doshi as a defendant, it does not discuss him as a party nor contain any allegations about his role in the transaction. Doshi is not participating in the instant appeal. 5 Subsequent to a June 25, 2009 raid by United States Marshals, Caraco entered into a consent decree with the FDA that stopped all production at Caraco’s facilities in Michigan until Caraco completed numerous remediation actions. In the fall of 2010, Caraco announced its intention to restart production of two generic drug products by the end of fiscal year 2011, and another two or three products by the third quarter of fiscal year 2012.

-2- merger agreement with Sun on or about February 22, 2011. Under the agreement, minority shareholders received $5.25 per share. The acquisition was completed on June 14, 2011.

Procedural History

On April 11, 2011, plaintiffs filed a four-count consolidated class-action complaint. In Count I, plaintiffs alleged that the going-private transaction (GPT) (i.e., the merger of Sun Pharmaceutical and Caraco) substantially underestimated Caraco’s true value and was not procedurally or financially fair to the minority shareholders. Plaintiffs alleged in Count II that defendants Shanghvi, Sachdeva, Desai, and Valia breached their fiduciary duties to Caraco’s public stockholders by favoring the interests of the majority shareholders and forcing through the GPT at an inadequate price. In Count III, plaintiffs alleged that defendants Sachdeva, Desai, and Valia aided and abetted Sun Pharmaceutical, Sun Global, and Shanghvi in their breach of the fiduciary duties they owed to plaintiffs. Finally, plaintiffs alleged in Count IV that defendants Bell, Munson, and Manney, the Independent Committee, breached their fiduciary duties to plaintiffs by agreeing to GPT terms that were exceedingly favorable to Sun at the expense of Caraco’s minority shareholders.

Defendants moved for summary disposition of plaintiffs’ complaint pursuant to MCR 2.116(C)(8). At the conclusion of an August 31, 2011 hearing, the trial court, Judge Gershwin A. Drain presiding, granted the motion. After the court announced its ruling, plaintiffs’ counsel requested leave to amend the complaint. Judge Drain denied the request for leave to amend, but implied that plaintiffs could include their request in a motion and brief for reconsideration. On October 11, 2011, plaintiffs filed a motion for reconsideration of the court’s order denying their request to amend the complaint. The trial court denied the motion in an order stating that plaintiffs had not met their burden of demonstrating that the matter warranted reconsideration. Plaintiffs appealed Judge Drain’s denial of their motion for leave to amend their complaint in this Court, which concluded that Judge Drain had abused his discretion “by denying plaintiffs the opportunity to provide legally sufficient allegations in an amended complaint . . . .” In re Caraco Pharm Laboratories, Ltd Shareholder Litigation, unpublished order of the Court of Appeals, issued March 27, 2013 (Docket No. 313893), p 3. The Court reversed Judge Drain’s order, and remanded the matter for further proceedings consistent with its opinion. Id. On remand, the trial court6 granted plaintiffs’ motion for leave to amend their complaint.

Generally speaking, the six-count amended complaint contained specific allegations of a scheme by Bell and Shanghvi to devalue Caraco’s stock in the months preceding the GPT in order to lower the cost of the GPT and to force the GPT to take place. Counts II through V paralleled the four counts raised in plaintiffs’ original complaint. Count I alleged that Bell breached fiduciary duties of loyalty and good faith by negotiating with Shanghvi to prevent Caraco from restarting its production activities and to terminate the distribution agreements between Sun Pharmaceutical and Caraco. Count VI alleged that the individual defendants had a

6 A different judge presided on remand because Judge Drain had begun serving on the federal bench.

-3- duty to ensure that minority shareholders received full and complete disclosures of all material facts regarding the GPT, and that such disclosures were not made.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Johnson v. Pastoriza
818 N.W.2d 279 (Michigan Supreme Court, 2012)
Mullins v. St. Joseph Mercy Hospital
741 N.W.2d 300 (Michigan Supreme Court, 2007)
Waltz v. Wyse
677 N.W.2d 813 (Michigan Supreme Court, 2004)
Abela v. General Motors Corp.
677 N.W.2d 325 (Michigan Supreme Court, 2004)
Tinman v. Blue Cross and Blue Shield
692 N.W.2d 58 (Michigan Court of Appeals, 2005)
Hubscher & Son, Inc v. Storey
578 N.W.2d 701 (Michigan Court of Appeals, 1998)
Webb v. Smith
568 N.W.2d 378 (Michigan Court of Appeals, 1997)
Mullins v. St Joseph Mercy Hospital
722 N.W.2d 666 (Michigan Court of Appeals, 2006)
Churella v. Pioneer State Mutual Insurance
671 N.W.2d 125 (Michigan Court of Appeals, 2003)
Maiden v. Rozwood
597 N.W.2d 817 (Michigan Supreme Court, 1999)
McNees v. Cedar Springs Stamping Co.
555 N.W.2d 481 (Michigan Court of Appeals, 1996)
Salvador v. Connor
276 N.W.2d 458 (Michigan Court of Appeals, 1978)
Horace v. City of Pontiac
575 N.W.2d 762 (Michigan Supreme Court, 1998)
Kidder v. Ptacin
771 N.W.2d 806 (Michigan Court of Appeals, 2009)
Rabkin v. Philip A. Hunt Chemical Corp.
498 A.2d 1099 (Supreme Court of Delaware, 1985)
People v. Albers
672 N.W.2d 336 (Michigan Court of Appeals, 2003)
Krieger v. Gast
122 F. Supp. 2d 836 (W.D. Michigan, 2000)
Bailey v. Schaaf
835 N.W.2d 413 (Michigan Supreme Court, 2013)
Dell v. Citizens Insurance Company of America
880 N.W.2d 280 (Michigan Court of Appeals, 2015)
Nuculovic v. Hill
287 Mich. App. 58 (Michigan Court of Appeals, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
in Re Caraco Pharmaceutical Laboratories Shareholder Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-caraco-pharmaceutical-laboratories-shareholder-litigation-michctapp-2017.